Skip to main content

Advertisement

Table 3 Base case analysis

From: Cost effectiveness of recombinant factor VIIa for treatment of intracerebral hemorrhage

Strategy Cost ($) Effectiveness (QALYs) Marginal Cost ($) Marginal Effectiveness (QALYs) Marg C/E ratio (Δ$/ΔQALYs)
rFVIIa $39,305 0. 40    
Usual Care $40,359 0. 29 $1,053. 20 -0. 11 ********
  1. ******** no mCER because rFVIIa dominates usual care by being both more effective and less costly.